Biomarker development in the precision medicine era: Lung cancer as a case study

Nature Reviews Cancer

Volumn 16, Issue 8, 2016, Pages 525-537

  Vargas, Ashley J ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENOMICS; HUMAN; INFORMATION PROCESSING; LUNG CANCER; METABOLOMICS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; LUNG NEOPLASMS; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; HUMANS; LUNG NEOPLASMS; PRECISION MEDICINE; PROGNOSIS;

EID: 84978116008     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.56     Document Type: Review

References (174)

1. Obama, B. Remarks by the President in State of the Union Address January 20, 2015. The White House https://www.whitehouse.gov/the-press-office/2015/01/20/remarks-president-state-union-address-january-20-2015 (2015
2. Collins, F. S., & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793-795 (2015
3. US National Institutes of Health (NIH). NIH workshop on building a precision medicine research cohort. NIH http://www.nih.gov/precisionmedicine/workshop.htm (2015
4. Elliott, P., Peakman, T. C., & Biobank UK. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37, 234-244 (2008
5. Frank, L. Epidemiology. When an entire country is a cohort. Science 287, 2398-2399 (2000
6. National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (National Academies Press, 2011
7. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014
8. Pepe, M. S., et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001
9. US Food and Drug Administration (FDA). In Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff (CBER/CDRH/FDA, 2014
10. Mansfield, E. A. FDA perspective on companion diagnostics: an evolving paradigm. Clin. Cancer Res. 20, 1453-1457 (2014
11. European Medicines Agency (EMEA). Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories (EMEA/CHMP/ICH, 2007
12. European Medicines Agency (EMA). Qualification of Novel Methodologies for Drug Development: Guidance to Applicants (EMA/CHMP/SAWP, 2009
13. Pharmaceuticals and Medical Devices Agency. Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products (Ministry of Health, Labour and Welfare, 2013
14. Pignatti, F., et al. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European Union. Clin. Cancer Res. 20, 1458-1468 (2014
15. Senderowicz, A. M., & Pfaff, O. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics. Clin. Cancer Res. 20, 1445-1452 (2014
16. Tazawa, Y. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan. Breast Cancer 23, 19-23 (2015
17. US Food and Drug Administration (FDA). FDA approves afatinib. FDA http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574. htm (2016
18. Lindeman, N. I., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 15, 415-453 (2013
19. McNeil, C. Regulating laboratory-developed tests: devil will be in details. J. Natl Cancer Inst. 107, djv113 (2015
20. US Food and Drug Administration (FDA). Administrative Procedures for CLIA Categorization: Guidance for Industry and Food and Drug Administration Staff (CDRH/DHHS/FDA, 2014
21. American Cancer Society. Cancer Facts, & Figures 2014. (American Cancer Society, 2014
22. Rodenhuis, S., et al. Mutational activation of the K ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317, 929-935 (1987
23. Paez, J. G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004
24. Campbell, J.D., et al. Distinct patterns of somatic genome alternations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48, 607-616 (2016
25. Kerr, K. M., et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann. Oncol. 25, 1681-1690 (2014
26. Korpanty, G. J., Graham, D. M., Vincent, M. D., & Leighl, N. B. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS 1, and KRAS. Front. Oncol. 4, 204 (2014
27. Dimou, A., & Papadimitrakopoulou, V. Non-small cell lung cancer beyond biomarkers: the evolving landscape of clinical trial design. J. Pers. Med. 4, 386-401 (2014
28. Kumar, M., Ernani, V., & Owonikoko, T. K. Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol. Aspects Med. 45, 55-66 (2015
29. Rooney, C., & Sethi, T. Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer. Chest 148, 1063-1072 (2015
30. Kwak, E. L., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010
31. Vallee, A., Le Loupp, A. G., & Denis, M. G. Efficiency of the Therascreen(R) RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. Clin. Chim. Acta 429, 8-11 (2014
32. European Medicines Agency (EMA). Giotrib (afatinib). EMA http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/002280/human-med-001698. jsp& mid=WC0b01ac058001d124 (2016
33. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012
34. Topalian, S. L., et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
35. Butkiewicz, D., et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 22, 593-597 (2001
36. Li, Y., et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 11, 321-330 (2010
37. Mechanic, L. E., et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol. Biomarkers Prev. 16, 214-222 (2007
38. Mechanic, L. E., et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 26, 597-604 (2005
39. Pine, S. R., et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J. Natl Cancer Inst. 99, 1401-1409 (2007
40. Ryan, B. M., et al. Identification of a functional SNP in the 3′UTR of CXCR2 that is associated with reduced risk of lung cancer. Cancer Res. 75, 566-575 (2015
41. Zhang, L., et al. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS ONE 7, e48350 (2012
42. Gerlinger, M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
43. Mazurek, A., et al. Quantification of concentration and assessment of EGFR mutation in circulating DNA. Cancer Biomark. 15, 515-524 (2015
44. Luo, J., Shen, L., & Zheng, D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci. Rep. 4, 6269 (2014
45. Pao, W., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005
46. Jamal-Hanjani, M., et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 12, e1001906 (2014
47. Beer, D. G., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8, 816-824 (2002
48. Bhattacharjee, A., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98, 13790-13795 (2001
49. Garber, M. E., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98, 13784-13789 (2001
50. Kikuchi, T., et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22, 2192-2205 (2003
51. Akagi, I., et al. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res. 73, 3821-3832 (2013
52. Chen, H. Y., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356, 11-20 (2007
53. Kadara, H., et al. A five-gene and corresponding protein signature for stage I lung adenocarcinoma prognosis. Clin. Cancer Res. 17, 1490-1501 (2011
54. Lee, E. S., et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin. Cancer Res. 14, 7397-7404 (2008
55. Okayama, H., et al. The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol. Biomarkers Prev. 23, 2884-2894 (2014
56. Oshlack, A., Robinson, M. D., & Young, M. D. From RNA-seq reads to differential expression results. Genome Biol. 11, 220 (2010
57. Govindan, R., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121-1134 (2012
58. Best, M. G., et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28, 666-676 (2015
59. Liloglou, T., Bediaga, N. G., Brown, B. R., Field, J. K., & Davies, M. P. Epigenetic biomarkers in lung cancer. Cancer Lett. 342, 200-212 (2014
60. Schmitt, A. M., & Chang, H. Y. Long noncoding RNAs in cancer pathways. Cancer Cell 29, 452-463 (2016
61. Fabbri, M., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl Acad. Sci. USA 109, E2110-E2116 (2012
62. Massie, C. E., & Mills, I. G. Chromatin immunoprecipitation (ChIP) methodology and readouts. Methods Mol. Biol. 505, 123-137 (2009
63. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996
64. Schumacher, A., Weinhausl, A., & Petronis, A. Application of microarrays for DNA methylation profiling. Methods Mol. Biol. 439, 109-129 (2008
65. Sandoval, J., et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J. Clin. Oncol. 31, 4140-4147 (2013
66. Shinjo, K., et al. Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 33, 1277-1285 (2012
67. Travis, W. D., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6, 244-285 (2011
68. Brunnstrom, H., et al. Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer study. Am. J. Clin. Pathol. 140, 37-46 (2013
69. Yanagisawa, K., et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362, 433-439 (2003
70. Zhukov, T. A., Johanson, R. A., Cantor, A. B., Clark, R. A., & Tockman, M. S. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40, 267-279 (2003
71. Kim, Y. J., et al. Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J. Proteome Res. 14, 1412-1419 (2015
72. Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
73. Alifano, M., et al. Preresection serum C reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 142, 1161-1167 (2011
74. Barrera, L., et al. Cytokine profile determined by data mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. Ann. Oncol. 26, 428-435 (2015
75. Enewold, L., et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 18, 215-222 (2009
76. Hong, S., Kang, Y. A., Cho, B. C., & Kim, D. J. Elevated serum C reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med. J. 53, 111-117 (2012
77. Ryan, B. M., Pine, S. R., Chaturvedi, A. K., Caporaso, N., & Harris, C. C. A combined prognostic serum interleukin 8 and interleukin 6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J. Thorac. Oncol. 9, 1494-1503 (2014
78. Song, G., et al. Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib. Clin. Chim. Acta 440, 44-48 (2015
79. Srimuninnimit, V., et al. C reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study). J. Med. Assoc. Thai. 95 (Suppl. 2), S199-S207 (2012
80. Füzéry, A. K., Levin, J., Chan, M. M., & Chan, D. W. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteom. 10, 13 (2013
81. Atkins, M. B., & Larkin, J. Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. J. Natl Cancer Inst. 108, djv414 (2016
82. Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275-287 (2016
83. European Medicines Agency (EMA). Keytruda (pembrolizumab). EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human-med-001886. jsp& mid=WC0b01ac058001d124 (2015
84. US Food and Drug Administration (FDA). FDA approves Keytruda for advanced non-small cell lung cancer. FDA http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm (2015
85. US Food and Drug Administration (FDA). FDA expands approved use of Opdivo to treat lung cancer. FDA http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm (2015
86. European Medicines Agency (EMA). Nivolumab BMS (nivolumab). EMA http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003840/human-med-001887. jsp& mid=WC0b01ac058001d124 (2016
87. US Food and Drug Administration (FDA). PHARMDX premarket approval. FDA http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P150013 (2015
88. Patel, S. P., & Kurzrock, R. PD L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847-856 (2015
89. Shukuya, T., & Carbone, D. P. Predictive markers for the efficacy of anti PD 1/PD L1 antibodies in lung cancer. J. Thorac. Oncol. http://dx.doi.org/10.1016/j. jtho.2016.02.015 (2016
90. Schalper, K. A., et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J. Natl Cancer Inst. 107, dju435 (2015
91. Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1, 153-161 (2002
92. Wishart, D. S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. http://dx.doi.org/10.1038/nrd.2016.32 (2016
93. Rocha, C. M., et al. NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. Carcinogenesis 36, 68-75 (2015
94. Wikoff, W. R., et al. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev. Res. (Phila.) 8, 410-418 (2015
95. Fahrmann, J. F., et al. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol. Biomarkers Prev. 24, 1716-1723 (2015
96. Hori, S., et al. A metabolomic approach to lung cancer. Lung Cancer 74, 284-292 (2011
97. Li, Y., Song, X., Zhao, X., Zou, L., & Xu, G. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time of flight mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 966, 147-153 (2014
98. Miyamoto, S., et al. Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time of flight mass spectrometry. Metabolites 5, 192-210 (2015
99. Carrola, J., et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 10, 221-230 (2011
100. Mathe, E. A., et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 74, 3259-3270 (2014
101. Castle, A. L., Fiehn, O., Kaddurah-Daouk, R., & Lindon, J. C. Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results. Brief. Bioinformat. 7, 159-165 (2006
102. Handelsman, J., Rondon, M. R., Brady, S. F., Clardy, J., & Goodman, R. M. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem. Biol. 5, R245-R249 (1998
103. Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl. Environ. Microbiol. 79, 5112-5120 (2013
104. Pragman, A. A., Kim, H. B., Reilly, C. S., Wendt, C., & Isaacson, R. E. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE 7, e47305 (2012
105. Segal, L. N., & Blaser, M. J. A brave new world: the lung microbiota in an era of change. Ann. Am. Thorac. Soc. 11 (Suppl. 1), S21-S27 (2014
106. Sapkota, A. R., Berger, S., & Vogel, T. M. Human pathogens abundant in the bacterial metagenome of cigarettes. Environ. Health Perspect. 118, 351-356 (2010
107. Heijink, I. H., Brandenburg, S. M., Postma, D. S., & van Oosterhout, A. J. Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery. Eur. Respir. J. 39, 419-428 (2012
108. Hosgood, H. D., et al. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ. Mol. Mutag. 55, 643-651 (2014
109. Castellarin, M., et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299-306 (2012
110. Flanagan, L., et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1381-1390 (2014
111. Kostic, A. D., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207-215 (2013
112. Kostic, A. D., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292-298 (2012
113. Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. Microbiome and anticancer immunosurveillance. Cell 165, 276-287 (2016
114. Cardona, S., et al. Storage conditions of intestinal microbiota matter in metagenomic analysis. BMC Microbiol. 12, 158 (2012
115. Santiago, A., et al. Processing faecal samples: a step forward for standards in microbial community analysis. BMC Microbiol. 14, 112 (2014
116. Wild, C. P. Complementing the genome with an exposome: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomarkers Prev. 14, 1847-1850 (2005
117. Spitz, M. R., et al. An expanded risk prediction model for lung cancer. Cancer Prev. Res. (Phila.) 1, 250-254 (2008
118. Spitz, M. R., et al. A risk model for prediction of lung cancer. J. Natl Cancer Inst. 99, 715-726 (2007
119. Wender, R., et al. American Cancer Society lung cancer screening guidelines. CA Cancer J. Clin. 63, 107-117 (2013
120. Khariwala, S. S., et al. Self-reported tobacco use does not correlate with carcinogen exposure in smokers with head and neck cancer. Laryngoscope 125, 1844-1848 (2015
121. Fagan, P., et al. Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer. Am. J. Public Health 105, 1237-1245 (2015
122. Hecht, S. S. Lung carcinogenesis by tobacco smoke. Int. J. Cancer 131, 2724-2732 (2012
123. Imielinski, M., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012
124. Gibbons, D. L., Byers, L. A., & Kurie, J. M. Smoking, p53 mutation, and lung cancer. Mol. Cancer Res. 12, 3-13 (2014
125. Takahashi, T., et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491-494 (1989
126. Dobbin, K. K., et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin. Cancer Res. 11, 565-572 (2005
127. Florkowski, C. M. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin. Biochem. Rev. 29 (Suppl. 1), S83-S87 (2008
128. Pagano, M., & Gauvreau, K. Principles of Biostatistics (ed. Crockett, C.) (Brooks/Cole, 2000
129. Polley, M. Y., et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J. Natl Cancer Inst. 105, 1677-1683 (2013
130. Rothman, K. J. Epidemiology: An Introduction (Oxford Univ. Press, 2012
131. Schork, N. J. Personalized medicine: time for one person trials. Nature 520, 609-611 (2015
132. Riely, G. J., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 14, 5731-5734 (2008
133. Yuan, Y., et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat. Biotechnol. 32, 644-652 (2014
134. Saito, M., et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin. Cancer Res. 17, 1875-1882 (2011
135. Robles, A. I., et al. An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA and DNA methylation biomarkers. J. Thorac. Oncol. 10, 1037-1048 (2015
136. Liu, C. Y., et al. Genome-wide gene-asbestos exposure interaction association study identifies a common susceptibility variant on 22q13.31 associated with lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 24, 1564-1573 (2015
137. US National Library of Medicine. Clinical Trials.gov, https://Clinical Trials.gov/ct2/show/NCT01248247?term=NCT01248247& rank=1 (2016
138. US National Library of Medicine. Clinical Trials.gov, https://Clinical Trials.gov/ct2/show/NCT01306045?term=NCT01306045& rank=1 (2016
139. Glass, K., Huttenhower, C., Quackenbush, J., & Yuan, G. C. Passing messages between biological networks to refine predicted interactions. PLoS ONE 8, e64832 (2013
140. Le Cao, K. A., Boitard, S., & Besse, P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics 12, 253 (2011
141. Liquet, B., Le Cao, K. A., Hocini, H., & Thiebaut, R. A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinformatics 13, 325 (2012
142. Valente, A. X., & Cusick, M. E. Yeast protein interactome topology provides framework for coordinated-functionality. Nucleic Acids Res. 34, 2812-2819 (2006
143. Wang, B., et al. Similarity network fusion for aggregating data types on a genomic scale. Nat. Methods 11, 333-337 (2014
144. Li, L., et al. Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat. Commun. 5, 5469 (2014
145. Kim, S. C., et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS ONE 8, e55596 (2013
146. International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993-998 (2010
147. Erler, J. T., & Linding, R. Network-based drugs and biomarkers. J. Pathol. 220, 290-296 (2010
148. Greene, C. S., et al. Understanding multicellular function and disease with human tissue-specific networks. Nat. Genet. 47, 569-576 (2015
149. Taylor, I. W., et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 27, 199-204 (2009
150. Chin, C. D., Linder, V., & Sia, S. K. Commercialization of microfluidic point of care diagnostic devices. Lab. Chip 12, 2118-2134 (2012
151. Day, N., et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br. J. Cancer 80 (Suppl. 1), 95-103 (1999
152. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control. Clin. Trials 19, 61-109 (1998
153. McCarty, C. A., et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genom. 4, 13 (2011
154. Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 9, e1001216 (2012
155. Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 10, 51 (2012
156. McShane, L. M., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Exp. Oncol. 28, 99-105 (2006
157. McShane, L. M., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Nat. Clin. Pract. Urol. 2, 416-422 (2005
158. McShane, L. M., et al. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23, 9067-9072 (2005
159. McShane, L. M., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2, 416-422 (2005
160. McShane, L. M., et al. Reporting recommendations for tumour marker prognostic studies (REMARK). Br. J. Cancer 93, 387-391 (2005
161. McShane, L. M., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97, 1180-1184 (2005
162. McShane, L. M., et al. Reporting recommendations for tumour marker prognostic studies (REMARK). Eur. J. Cancer 41, 1690-1696 (2005
163. Srivastava, S. The early detection research network: 10 year outlook. Clin. Chem. 59, 60-67 (2013
164. McRonald, F. E., et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev. Res. (Phila.) 7, 362-371 (2014
165. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409 (2011
166. Schmidt, C. Lung cancer screening poised to expand. J. Natl Cancer Inst. 107, djv114 (2015
167. Ma, J., Ward, E. M., Smith, R., & Jemal, A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer 119, 1381-1385 (2013
168. Pinsky, P. F., & Berg, C. D. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J. Med. Screen. 19, 154-156 (2012
169. Patz, E. F. Jr, et al. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(15)00621-X (2016
170. Lee, H. Y., et al. Role of CT and PET imaging in predicting tumor recurrence and survival in patients with lung adenocarcinoma: a comparison with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma. J. Thorac. Oncol. 10, 1785-1794 (2015
171. Ruparel, M., et al. Pulmonary nodules and CT screening: the past, present and future. Thorax 71, 367-375 (2016
172. Elmore, J. G., et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N. Engl. J. Med. 338, 1089-1096 (1998
173. Ahmad, A., & Gadgeel, S. M. (eds) Lung Cancer and Personalized Medicine (Springer, 2016
174. Alberg, A. J., & Samet, J. M. Epidemiology of lung cancer. Chest 123, 21S-49S (2003